← Back to results

J Control Release · 2015

Current and future delivery systems for engineered nucleases: ZFN, TALEN and RGEN.

Journal of controlled release : official journal of the Controlled Release Society, 205: 120-7 PMID 25553825 DOI 10.1016/j.jconrel.2014.12.036

Open in PubMed ↗ Open via DOI ↗

Abstract

Gene therapy by engineered nucleases is a genetic intervention being investigated for curing the hereditary disorders by targeting selected genes with specific nucleotides for establishment, suppression, abolishment of a function or correction of mutation. Here, we review the fast developing technology of targeted genome engineering using site specific programmable nucleases zinc finger nucleases (ZFNs), transcription activator like nucleases (TALENs) and cluster regulatory interspaced short palindromic repeat/CRISPR associated proteins (CRISPR/Cas) based RNA-guided DNA endonucleases (RGENs) and their different characteristics including pros and cons of genome modifications by these nucleases. We have further discussed different types of delivery methods to induce gene editing, novel development in genetic engineering other than nucleases and future prospects.

Cite